1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4)

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4) is an enzyme that hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate the second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), regulating intracellular calcium signaling and protein kinase C activation[2][3][4][8]. PLCB4 plays critical roles in craniofacial development, notably in the first and second pharyngeal arches, is essential for normal visual processing in the retina, and contributes to bone metabolism through osteoclast differentiation pathways[1][5][7]. Mutations in PLCB4 cause auriculocondylar syndrome, leading to characteristic facial and jaw malformations[1][2]. PLCB4 is a member of the phosphoinositide-specific phospholipase C family, acts in several GPCR-linked signaling cascades, and is a potential therapeutic target in disorders involving abnormal bone resorption or craniofacial development[2][7]. Directly targeting PLCB4 pharmacologically is not established clinically, but its biological pathways are of significant interest.

Other names

Phospholipase C beta 4PLC-beta-4Phosphoinositide phospholipase C-beta-4ARCND2PI-PLCDJ1119D9.2Monophosphatidylinositol phosphodiesterase1-phosphatidyl-D-myo-inositol-4,5-bisphosphate phosphodiesterase beta-4

Not directly drugged in current clinical practice. Theoretical: - Inhibition or modulation would alter intracellular calcium release and protein kinase C activation by affecting second messenger generation (diacylglycerol and inositol trisphosphate)[2][3][4]. - Potential pathway modulation in osteoclastogenesis (RANKL–MKK3–p38 MAPK)[7].